Forteo Trial on Idiopathic Osteoporosis in Premenopausal Women
NCT01440803 is a phase 2 interventional trial sponsored by Elizabeth Shane. As of 21 Nov 2026, it is completed. It studies Saline Placebo and Teriparatide in Adult Idiopathic Generalized Osteoporosis. The registry lists an enrollment of 41 participants at 2 sites in 1 country. The registry lists a start date of 2 Aug 2012 and a primary completion date of 1 Jan 2018.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT01440803 |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional trial |
| Lead sponsor | Elizabeth Shane |
| Enrollment | 41 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Adult Idiopathic Generalized Osteoporosis |
| Drugs | Saline Placebo and Teriparatide |
| Start | 2 Aug 2012 |
| Primary completion | 1 Jan 2018 |
| Study completion | 1 Feb 2019 |
| Last update posted | 11 Dec 2019 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Adi Cohen, MD
Columbia University
Study Director - Elizabeth Shane, MD
Columbia University
Principal Investigator - Emily M Stein, MD
Columbia University
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Creighton University
Omaha
- Columbia University Medical Center
New York
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT01440803
Each answer restates registry values shown on this page.
What is NCT01440803?
NCT01440803 is a phase 2 interventional trial sponsored by Elizabeth Shane. It studies Saline Placebo and Teriparatide in Adult Idiopathic Generalized Osteoporosis.
Who leads NCT01440803?
The registry names Adi Cohen, MD (study director, Columbia University), Elizabeth Shane, MD (principal investigator, Columbia University) and Emily M Stein, MD (study director, Columbia University) as overall officials.
Where does NCT01440803 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT01440803 study?
The registered drug and biological interventions are Saline Placebo and Teriparatide.
When did NCT01440803 end?
The registry lists a primary completion date of 1 Jan 2018 and a study completion date of 1 Feb 2019. The sponsor last updated the record on 11 Dec 2019.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.